Apogee: 'Hold' On AbbVie $10.9B Buyout And Extended Half-Life IL-13 Zumilokibart For AD
· seekingalpha.com
Apogee Therapeutics is being acquired by AbbVie for $135.11 per share in cash, capping further upside. Click here to read my most recent analysis of APGE.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...